1YBottom 25% of the group
Rank 60 of 63 funds
Return +4.98%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 60No. 1 is SCBGENOME(E) +68.99%
TISCO Global Digital Health Equity Fund
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
TGHDIGI invests through the master fund UBS (Lux) Digital Health Equity 99.54%
This fundTGHDIGI
The fund that actually investsUBS (Lux) Digital Health EquityThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Unitedhealth Group UNH4.88%
Eli Lilly and Co LLY3.98%Over the past year it was in the bottom 25% of its group; over 5 years it returned −10.92% per year (Bottom 25% of the group)
No. 1 is SCBGENOME(E) +68.99%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.43% | +1.82% | +4.47% | +6.75% | +11.80% | +19.06% | +4.98% | +24.72% | −43.90% | +7.58% | +4.11% |
Total return over each period, matching the NAV chart periods · Not annualised
Largest drawdown in the selected period −66.36% Previous peak 15 Feb 2021 (NAV 22.4024) → Trough 30 Oct 2023 (NAV 7.5365) · Not back to the previous peak as of 3 Nov 2026
Currently −53.53% from the peak NAV of 22.4024 (15 Feb 2021)
Over 5 years, TGHDIGI returned -0.37 per unit of volatility, ranking 28 of 33 funds · The highest is FP HCARE-A (0.44)
กองทุนจะเน้นลงทุนในหน่วยลงทุนของกองทุน UBS (Lux) Digital Health Equity ชนิดหน่วยลงทุน I-A2-acc (กองทุนหลัก) ซึ่งมีนโยบายการลงทุนอย่างน้อย 80% ของมูลค่าทรัพย์สินสุทธิของกองทุนในตราสารทุน หลักทรัพย์ที่เกี่ยวข้องกับตราสารทุน และใบแสดงสิทธิต่างๆ ที่ออกโดยบริษัทที่ใช้นวัตกรรมและเทคโนโลยีในการนำเสนอผลิตภ… Its largest holdings are UBS LUX DIGITAL HEALTH EQUITY FUND I-A2-ACC 99.54% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 1 Mar 2019, its NAV has fallen as much as −66.36% from its peak.
Actual total expense ratio (TER) 1.29% a year, against a ceiling of 5.00%. Management fee 1.07%. Front-end fee 1.25%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
Hedged at the manager's discretion. As of 30 Sep 2026, 91.05% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
AstraZeneca AZN.L
Guardant Health GH3.48%
Natera NTRA3.48%
Intuitive Surgical ISRG3.38%
Philips PHG2.89%
Vertex Pharmaceuticals VRTX2.69%Hospitals, medicines and medical equipment
Eli Lilly and Co LLYDiabetes and weight-loss drugs
AstraZeneca AZN.LHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Natera NTRAUS company that runs DNA blood tests for prenatal screening, cancer monitoring and organ transplants
Intuitive Surgical ISRGHospitals, medicines and medical equipment
Swiss company making generic medicines and biosimilars cheaper than the originals, spun off from Novartis
Philips PHGDutch company making MRI and ultrasound scanners, patient monitors and Sonicare electric toothbrushes
Makes cystic fibrosis drugs and a gene-editing therapy for thalassaemia
American company that makes and delivers medical supplies such as gloves, surgical gowns and dressings to hospitals
Based on the master fund's share of this fund's value (99.54% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from UBS · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +22.37% per year
No. 1 is FP HCARE-A +6.71% per year
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.3 | −1.1 | −9.7 | +2.4 | +0.8 | +8.9 | −4.0 | +8.7 | −0.8 | +5.3 | −0.5 | · | +7.4* |
| 2025 | +9.5 | −6.6 | −9.4 | +5.8 | −2.5 | +5.2 | −3.2 | +4.8 | +2.6 | +5.4 | +1.3 | −4.2 | +7.2 |
| 2024 | −6.0 | +7.4 | −1.2 | −10.7 | −0.5 | +1.0 | +5.0 | +1.1 | +0.5 | −5.3 | +7.7 | −9.3 | −11.7 |
| 2023 | +9.0 | −2.6 | −2.2 | +2.9 | +1.4 | +4.5 | +3.5 | −12.1 | −12.1 | −13.2 | +14.9 | +16.3 | +5.0 |
| 2022 | −17.6 | −0.9 | −0.1 | −19.5 | −6.3 | +2.9 | +15.8 | −3.5 | −9.7 | +2.5 | +3.4 | −7.6 | −37.3 |